

NEUROSCIENTIFIC SIGNS MANUFACTURING AGREEMENT WITH MITSUBISHI

Perth, Australia; 20 April 2020: NeuroScientific Biopharmaceuticals Ltd (ASX:NSB, "NSB" or the "Company"), is pleased to announce that the Company has signed a manufacturing service agreement with leading Japanese company Mitsubishi Corporation (Mitsubishi).

Under the terms of the agreement, the Mitsubishi invested company PeptiStar Inc. (Peptistar) will perform feasibility and analytical services for the large-scale manufacturing of EmtinB drug product for NSB's future clinical programs, scheduled to begin in the second half of 2020.

NSB's CEO & Managing Director, Matt Liddelow, stated, "NSB is excited to be working with PeptiStar and its globally recognized parent company, Mitsubishi. These companies will add significant peptide manufacturing expertise to NSB's clinical development programs and we hope this agreement will be the first step towards a long-term manufacturing partnership with Mitsubishi and PeptiStar."

End

About NeuroScientific Biopharmaceuticals Ltd

NSB (ASX:NSB) is a drug development company focused on developing peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. The Company's product portfolio includes lead drug candidate EmtinB, a novel therapeutic peptide most advanced as a treatment for Alzheimer's disease; and other related peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

Contacts

Matthew Liddelow CEO and Managing Director ml@neuroscientific.com +61 8 6382 1805 Brian Leedman Chairman bl@neuroscientific.com +61 412 281 780